[go: up one dir, main page]

EA201591331A1 - Антагонисты il-33 и их применение - Google Patents

Антагонисты il-33 и их применение

Info

Publication number
EA201591331A1
EA201591331A1 EA201591331A EA201591331A EA201591331A1 EA 201591331 A1 EA201591331 A1 EA 201591331A1 EA 201591331 A EA201591331 A EA 201591331A EA 201591331 A EA201591331 A EA 201591331A EA 201591331 A1 EA201591331 A1 EA 201591331A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
antagonists
present
protein
applications
Prior art date
Application number
EA201591331A
Other languages
English (en)
Other versions
EA034834B1 (ru
Inventor
Эндрю Дж. МЕРФИ
Николас Дж. Пападопулос
Джейми Оренго
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201591331A1 publication Critical patent/EA201591331A1/ru
Publication of EA034834B1 publication Critical patent/EA034834B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем изобретении предлагаются антагонисты интерлейкина-33 (IL-33), включающие один или несколько IL-33-связывающих доменов и один или более мультимеризующих доменов, и способы их применения. Согласно некоторым вариантам реализации изобретения IL-33-связывающие домены могут содержать IL-33-связывающий участок белка ST2 и/или внеклеточный участок белка IL-1RAcP. Антагонисты IL-33 по данному изобретению могут применяться для лечения заболеваний и патологий, связанных с передачей сигнала IL-33 и/или клеточной экспрессией IL-33, таких как инфекционные заболевания, воспалительные заболевания, аллергические заболевания и фиброзные заболевания.
EA201591331A 2013-03-15 2014-03-14 Антагонисты il-33 и их применение EA034834B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361787121P 2013-03-15 2013-03-15
US201361819029P 2013-05-03 2013-05-03
US201361913417P 2013-12-09 2013-12-09
PCT/US2014/027058 WO2014152195A1 (en) 2013-03-15 2014-03-14 Il-33 antagonists and uses thereof

Publications (2)

Publication Number Publication Date
EA201591331A1 true EA201591331A1 (ru) 2016-01-29
EA034834B1 EA034834B1 (ru) 2020-03-26

Family

ID=50513479

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591331A EA034834B1 (ru) 2013-03-15 2014-03-14 Антагонисты il-33 и их применение

Country Status (12)

Country Link
US (3) US9637535B2 (ru)
EP (1) EP2968454B1 (ru)
JP (1) JP6404314B2 (ru)
KR (1) KR20150127591A (ru)
CN (1) CN105007929B (ru)
AU (1) AU2014240101B2 (ru)
CA (1) CA2904377C (ru)
EA (1) EA034834B1 (ru)
HK (1) HK1220373A1 (ru)
IL (1) IL240393B (ru)
MX (1) MX364591B (ru)
WO (1) WO2014152195A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11492398B2 (en) 2017-08-31 2022-11-08 Mitsubishi Tanabe Pharma Corporation IL-33 antagonist-containing therapeutic agent for endometriosis
US11725049B2 (en) 2013-12-26 2023-08-15 Mitsubishi Tanabe Pharma Corporation Human anti-IL-33 neutralizing monoclonal antibody

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
KR20150127591A (ko) 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
KR102446386B1 (ko) 2014-01-10 2022-09-22 아납티스바이오, 아이엔씨. 인터루킨-33 (il-33)에 대한 항체
CA2946511C (en) 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
AU2015292678B2 (en) 2014-07-22 2020-10-22 Cb Therapeutics, Inc. Anti-PD-1 antibodies
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
ES3000557T3 (en) 2015-03-02 2025-02-28 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
EP3359567A2 (en) * 2015-10-06 2018-08-15 Regeneron Pharmaceuticals, Inc. Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
WO2017087838A2 (en) * 2015-11-19 2017-05-26 George Mason University Dual inhibitory action peptidomimetic inhibitor for il-33 and il-1beta
CA3011547A1 (en) * 2016-01-14 2017-07-20 Anaptysbio, Inc. Inhibition of allergic reaction using an il-33 inhibitor
BR112018071276A2 (pt) 2016-04-27 2019-02-12 Pfizer Inc. anticorpos anti-il-33, composições, métodos e usos dos mesmos
AU2017258097B2 (en) 2016-04-27 2019-10-24 Abbvie Inc. Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
CN106198953B (zh) * 2016-07-19 2018-06-29 重庆医科大学 白介素-33在制备诊断肺源性急性肺损伤试剂盒中的用途
ES2971881T3 (es) 2016-08-19 2024-06-10 Beigene Switzerland Gmbh Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
EP3580240A1 (en) 2017-02-10 2019-12-18 H. Hoffnabb-La Roche Ag Anti-tryptase antibodies, compositions thereof, and uses thereof
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
IL314591A (en) 2017-04-13 2024-09-01 Regeneron Pharma Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
CN110997725B (zh) 2017-06-12 2024-08-09 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
US20190010531A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
AU2018392334A1 (en) 2017-12-22 2020-05-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
CA3088557C (en) 2018-02-09 2024-02-27 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
SG11202006310PA (en) 2018-02-28 2020-07-29 Regeneron Pharma Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
DK3768709T3 (da) 2018-03-19 2024-01-29 Regeneron Pharma Mikrochip-kapillærelektroforese-assays og reagenser
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantification of IL-33
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
WO2020046793A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
SG11202011969WA (en) 2018-08-30 2020-12-30 Regeneron Pharma Methods for characterizing protein complexes
EA202191841A1 (ru) 2019-01-16 2021-10-07 Ридженерон Фармасьютикалз, Инк. Способы для идентификации свободных тиолов в белках
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
US12246305B2 (en) 2019-09-24 2025-03-11 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
IL293112A (en) 2019-11-25 2022-07-01 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
JP2023517345A (ja) 2020-03-13 2023-04-25 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
CN115315527A (zh) 2020-03-13 2022-11-08 免疫医疗有限公司 用于治疗il33中存在风险等位基因的受试者的治疗方法
KR20220164555A (ko) 2020-04-06 2022-12-13 메디뮨 리미티드 Il-33 축 결합 길항제를 사용한 급성 호흡 곤란 증후군의 치료
US12163122B2 (en) 2020-08-31 2024-12-10 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
US12239687B2 (en) 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Fabrication of protein-encapsulating microgels
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
US20220404369A1 (en) 2021-03-03 2022-12-22 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
JP2024519407A (ja) 2021-03-26 2024-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 混合プロトコルを作成するための方法およびシステム
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
US20240327483A1 (en) * 2021-07-24 2024-10-03 Anwita Biosciences, Inc. Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
JP2024538673A (ja) 2021-10-07 2024-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ｐＨモデリング及び制御のシステム及び方法
JP2024541952A (ja) 2021-10-26 2024-11-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 実験室用水を生成し、実験室用水を異なる温度で分配するためのシステム及び方法
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
US20240198253A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
US20240366471A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000056A (en) 1910-11-03 1911-08-08 Carlos Van Bergh Threshing-machine.
US1001164A (en) 1911-06-09 1911-08-22 Arthur W Porter Cotton-sweep.
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US20070042978A1 (en) 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8865645B2 (en) * 2006-05-24 2014-10-21 Biogen Idec Ma Inc. Method of treating lung fibrosis using ST2 polypeptide
AT502353B1 (de) 2006-06-29 2007-07-15 Avl List Gmbh Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
EP2152740A1 (en) 2007-04-26 2010-02-17 Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Products for altering il-33 activity and methods therefor
WO2008144610A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
US20100310575A1 (en) 2007-10-26 2010-12-09 Max-Planck-Gesellschaft Zur Forderung Der Wissensc Inhibitors of Caspase I-Dependent Cytokines in the Treatment of Neurodegenerative Disorders
CN112481367A (zh) * 2008-03-31 2021-03-12 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
KR20150127591A (ko) 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
KR102446386B1 (ko) 2014-01-10 2022-09-22 아납티스바이오, 아이엔씨. 인터루킨-33 (il-33)에 대한 항체

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11725049B2 (en) 2013-12-26 2023-08-15 Mitsubishi Tanabe Pharma Corporation Human anti-IL-33 neutralizing monoclonal antibody
US11492398B2 (en) 2017-08-31 2022-11-08 Mitsubishi Tanabe Pharma Corporation IL-33 antagonist-containing therapeutic agent for endometriosis

Also Published As

Publication number Publication date
US20140271642A1 (en) 2014-09-18
HK1220373A1 (zh) 2017-05-05
US20170204158A1 (en) 2017-07-20
CA2904377A1 (en) 2014-09-25
US10774128B2 (en) 2020-09-15
US10011647B2 (en) 2018-07-03
IL240393A0 (en) 2015-09-24
WO2014152195A1 (en) 2014-09-25
US20180265567A1 (en) 2018-09-20
JP2016515130A (ja) 2016-05-26
MX2015011408A (es) 2016-04-27
KR20150127591A (ko) 2015-11-17
JP6404314B2 (ja) 2018-10-10
EP2968454A1 (en) 2016-01-20
NZ712651A (en) 2021-04-30
IL240393B (en) 2019-03-31
MX364591B (es) 2019-05-02
AU2014240101A1 (en) 2015-10-15
AU2014240101B2 (en) 2018-05-17
EA034834B1 (ru) 2020-03-26
US9637535B2 (en) 2017-05-02
EP2968454B1 (en) 2019-02-13
CN105007929B (zh) 2019-05-10
CA2904377C (en) 2021-07-13
CN105007929A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
EA201591331A1 (ru) Антагонисты il-33 и их применение
EA201591716A1 (ru) Антитела анти-il-33 и их применение
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
IL256079B1 (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201790377A1 (ru) Антитела к глюкагону и их применения
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
EA201691027A1 (ru) Модуляторы aplnr и их применение
PT2953969T (pt) Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios
CY1122701T1 (el) Απελευθερωση πρωτεϊνης με βαση βακτηρια
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201591376A1 (ru) Конструкции антител к cdh19 и cd3
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
MD20150100A2 (ru) Вирусы болезни Ньюкасла и их использование
EA201300239A1 (ru) Антитела к fap и способы их применения
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
MX375524B (es) Anticuerpos anti-axl.
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU